Practical Management of MS in the Primary Care Office Setting Case Study 3.

Slides:



Advertisements
Similar presentations
Practicalities of Palliative Care
Advertisements

1 0N-SITE TREATMENT OF HEPATITIS C - A PILOT STUDY Shay Keating, MB, PhD Medical Officer.
Arden L Aylor, MD Geriatrics.  Health Maintenance  Quick office screening tools  Advance Directives  Driving issues  Care types  Placement.
Shared Care Panel Discussion Caring for your Patient with Arthritis.
Palliative Sedation Pam Mansfield, MD, CCFP October 2, 2009.
150 new referrals / year 150 new referrals / year Mainly schizophrenia, schizoaffective disorder, bipolar, drug induced psychosis, dual diagnosis Mainly.
PAH Mohammad Ruhal Ain R Ph, PGDPRA, M Pharm (Clin. Pharm) Department of Clinical Pharmacy Salman Bin AbdulAziz University College Of Pharmacy.
Session III: Providing Progestin-Only Injectables
SUA
Dose-Toxicity Study of Oral Prednisone in Ocular Myasthenia Michael Benatar, Mike McDermott, Gil Wolfe and Don Sanders.
I MMUNITY : R HEUMATOID A RTHRITIS A C ASE S TUDY Beth Downing, MSN, RN-BC, ONC.
The Prostate Net Pain Management for Patients and Caregivers Biren Saraiya MD The Cancer Institute of New Jersey.
The Prostate Net Pain management for patients and caregivers Biren Saraiya MD The Cancer Institute of New Jersey.
Treatment of Arthritis.  Arthritis is a form of joint disorder that involves inflammation of one or more joints. inflammation  There are over 100 different.
1 Lotronex ® (alosetron HCl) Tablets Risk-Benefit Issues Victor F. C. Raczkowski, M.D. Director, Division of Gastrointestinal and Coagulation Drug Products.
“My migraine always comes back” Presented by: Julio Pascual Neuroscience Area, Service of Neurology, University Hospital Central de Asturias and Ineuropa,
Restless Leg Syndrome Case Study James A. Rowley, MD for the Sleep Education for Pulmonary Fellows and Practitioners, SRN ATS Committee May 2015.
Math Meeting Write today’s date. __________________________ What was the date 4 months & 1 day ago?___________________________ What season was it?
Treatment of Arthritis Dr. Kaukab Azim. Medicinal Treatment for Arthritis Pain Relief: The most common medication used for acute pain relief are.
The Growing Knee OA Population
Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD A double-blind, randomised, non-inferiority, parallel-group,
NYU Medicine Grand Rounds Clinical Vignette Himali Weerahandi, PGY3 March 6, 2012 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.
 1. A care plan is developed for each of the patient's medical conditions being managed with pharmacotherapy.  2. A goal of therapy is the desired response.
Hospice Basics: Palliative Care vs. Curative Care.
Case Study: Scope and Purpose This Case Study was developed to demonstrate the use of IMI telemedicine technology in a “real life” ophthalmic clinical.
PATIENT CASE Module 4 Date of preparation: June 2015 HQ/EFF/15/0024h.
HEALTH CARE DECISIONS ACROSS THE TRAJECTORY OF ILLNESS Susan Barbour RN MS ACHPN.
Pharmacotherapy III Fall The International Association for the Study of Pain defines pain as an unpleasant sensory and emotional experience associated.
C-BR- 1 Raptiva ™ (efalizumab) Benefit:Risk Assessment Charles Johnson, MB, ChB Senior Director Head of Specialty Biotherapeutics Genentech, Inc.
Problem Behaviors Norman Wetterau. Less serious Ran of out pills three days early After one year lost pills Had a headache and a friend gave her a vicodin.
Katy Trinkley, PharmDAngie Thompson, PharmD.  Opioid risks and risk prevention strategies  Medication treatment by pain type  Fundamental principles.
Unit 5 Isoniazid Prevention Therapy: B Family Case Botswana National Tuberculosis Programme Manual Training for Medical Officers.
Community Pharmacy Cheshire & Wirral (CPCW) Helen Murphy Chief Executive Officer Community Pharmacy Cheshire and Wirral.
Therapeutic Drug Monitoring (TDM) Sticker Project A New Method for Documenting Times of Medication Doses and Drug Levels.
Prophylaxis of Opportunistic Infections
Maintenance Therapy with Bortezomib plus Thalidomide (VT) or Bortezomib plus Prednisone (VP) in Elderly Myeloma Patients Included in the GEM2005MAS65 Spanish.
Natalizumab- Unmet Need in the Management of Crohn’s Disease Doug Wolf, M.D. Atlanta Gastroenterology Associates July 31, 2007.
Pain II: Cancer Pain Management Dr. Leah Steinberg.
Group B presentation – Inderpreet Kaur (GPST1). Scenario A 27 year old lady presents to you as a newly registered patient in your practice. She had recently.
Advisory Committee for Peripheral and Central Nervous System Drugs March 7, 2006 Question 1: 1.Has Biogen demonstrated natalizumab’s efficacy on reduced.
Component 4 Medications. Key Points - Medications  2 general classes: – Long-term control medications – Quick-Relief medications  Controller medications:
COMMUNITY PHARMACY WORKBOOK PUBLIC HEALTH DORSET
Dr John Cox Diabetes in Primary Care Conference Cork
Choosing Wisely Pharmacy’s Role and Recommendations Mary Wong
Pneumococcal Vaccination Small group cases:Facilitator’s Guide
MULTIPLE SCLEROSIS COMPLICATED BY FETAL EARLY ONSET GROWTH RESTRICTION – Possible effect of disease modifying drugs Dr.Muzibunnisa Begam1, Dr.Howaida.
Understanding Legal Principles in Health Care
Section III: Pharmacological Therapies
Module 4: Role Playing and Case Discussions
Dr Alison Giles Palliative Medicine Consultant
Figure 1 An example of individual prediction of response to interferon β-1a and natalizumab in moderately advanced, active multiple sclerosis. Six treatment.
Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.
NR 508Competitive Success/tutorialrank.com
NR 508 Education for Service-- tutorialrank.com. NR 508 Week 1 Discussions For more course tutorials visit Discussion Part One Emily,
Monitoring and Modifying Treatment in PAH
Headache Script Setting and patient details
Parkinson Disease:.
Patient 1: 53-Year-Old Man With CVD Risk Factors
Pain Management: Patients Maintained on Buprenorphine
Program Goals Overview Glatiramer Acetate 3 Times a Week.
Management of Systematic Lupus Erythematosus
Shared Care Panel Discussion
TREATMENT OF THE ACUTE GOUT ATTACK:
Calculating and Using Morphine Equivalent Doses of Opioids
Program Goal. Program Goal Disclaimer Overview.
COMMUNITY PHARMACY WORKBOOK 2019 PUBLIC HEALTH DORSET
Treatment of Multiple Sclerosis: Old & New
MS Relapse Management: Team Approaches Colleen Harris MN NP MSCN
CASE STUDIES.
Algorithm based on the 2015 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) recommendations for the management of polymyalgia.
Presentation transcript:

Practical Management of MS in the Primary Care Office Setting Case Study 3

Case 3 Managing Adverse Events Ms. M, 23-year-old woman newly diagnosed with MS Initiated on interferon beta-1a IM weekly – 1st dose 48 hours ago Calls office today with complaints of horrible flu-like symptoms for over 24 hours after her 1st dose Discussion question: What triage questions should you ask her?

Case 3 Triage Questions Did she premedicate with any pain relievers/antipyretics? –Acetaminophen? NSAID? Did she take any medication (eg, acetaminophen or NSAID) around the clock after dosing? What dose of interferon beta-1a did she take?

Case 3 Patient Responses Ms. M did not premedicate She did not use acetaminophen or NSAID postdose She gave herself the full dose of interferon beta-1a; she did not know to titrate the dose

Case 3 Instructions to Patient Premedicate with naproxen 500 mg before administering interferon and then dose every 812 hours if needed Reduce interferon beta-1a dose to ½ for 2 weeks, then ¾ dose for 2 weeks, then full dose Follow up in clinic in about 1 month

Case 3 Clinic Follow-Up 5 Weeks Later Ms. M reports that she tolerated 1/2 dose and 3/4 dose without problem She is having minor flu-like symptoms with full dose

Case 3 Clinic Follow-Up 6 Months Later Ms. M reports being laid up for 24 or more hours each week after interferon beta-1a dose She is taking naproxen 500 mg before dosing and around the clock afterward She has skipped the last few interferon doses and is thinking about discontinuing treatment completely because it is just not worth it Discussion question: What options would you discuss with her?

Case 3 Options Discussed Switch to a different disease-modifying therapy (especially glatiramer acetate) Prednisone 10 mg weekly with interferon beta-1a IM dose No treatment –She should be informed of the benefits of early disease-modifying therapy, which she would be losing by choosing no treatment

Case 3 Ms. Ms Choice Ms. M is engaged in a discussion regarding all of her options She recognizes the benefits of early treatment, and indicates a desire to continue on some form of MS disease-modifying therapy She does not want to inject more than once weekly, so she decides to continue interferon beta-1a IM but with the addition of prednisone Another follow-up is scheduled in 1 month

Case 3 Clinic Follow-Up 1 Month Later Ms. M is tolerating interferon beta-1a at full dose She has had minimal to no side effects with prednisone